1,5-benzodiazepine derivatives having CCK and/or gastrin antagonistic activity
US5585376A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Oct 30, 1995 |
| Grant date | Dec 17, 1996 |
| Priority date | — |
| Expiry date | Oct 30, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compounds of general formula (I) ##STR1## and physiologically acceptable salts thereof wherein the group NR.sub.1 R.sub.2 represents a 5-7 membered saturated heterocyclic ring which may be substituted by one or two methyl groups; R.sub.3 is C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl or phenyl optionally substituted by 1 or 2 halogen atoms; R.sub.4 is phenyl or phenyl substituted by one or two groups selected from the group consisting of halogen, C.sub.1-4 alkyl, trifluoromethyl, trifluoromethoxy or (CH.sub.2).sub.n R.sub.5 wherein n is zero or 1 and R.sub.5 represents C.sub.1-4 alkoxy, hydroxy, nitro, cyano, CO.sub.2 R.sub.6, S(O).sub.p CH.sub.3, NR.sub.7 R.sub.8, CONR.sub.7 R.sub.8, SO.sub.2 NR.sub.7 CO(C.sub.1-4)alkyl, tetrazolyl, carboxamidotetrazolyl, or a 3-trifluoromethyl 1,2,4-triazolyl; R.sub.6 is hydrogen, C.sub.1-4 alkyl or benzyl; R.sub.7 is hydrogen or C.sub.1-4 alkyl, R.sub.8 is hydrogen, C.sub.1-4 alkyl, SO.sub.2 CH.sub.3 or SO.sub.2 CF.sub.3, X represent hydrogen, C.sub.1-4 alkyl or halogen; m is zero, 1 or 2, and p is zero, 1 or 2. The invention also relates to processes for preparation of these compounds and to their use in medicine as a…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.